Skip to main content
Caplight Logo









Telomere Therapeutics

Telomere Therapeutics

Private
BarcelonaHealthcare & Life Scienceshttps://telomere-tx.com/

Last Round

Accelerator

Dec 13, 2023

Total Funding Raised

$2.32M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Telomere Therapeutics is a gene therapy company developing disease modifying treatments for unmet medical needs, pioneering the repair of telomeres to treat organ fibrosis and other telomere-dysfunction syndromes.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

gene therapytelomere repairAAV gene therapyidiopathic pulmonary fibrosisIPFlongevity biotechtelomere dysfunctionTERT gene therapyregenerative medicineadeno-associated virusAAVanti-aging therapyfibrotic diseasescellular agingpreclinical biotechtelomerase reverse transcriptase

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Telomere Therapeutics Comparables

Compare Telomere Therapeutics with similar companies based on industry and business-model similarity.

Telomere Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Rejuvenation Technologies
78%
PureTech Health
62%
Roche Holding
62%

Telomere Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AcceleratorDec 13, 2023
GrantJan 1, 2022
SeedMay 25, 2021

Key People

Founding team and executive leadership

Michael Tadros

CEO

Executive Team

Telomere Therapeutics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 22, 2026

    Monthly visitors grew 67% MoM, reaching 1.8K.

  • Jul 24, 2026

    Monthly visitors grew 233% MoM, reaching 1.1K.

Telomere Therapeutics Filings

Explore SEC and related filing metadata, where available.

Telomere Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Telomere Therapeutics's valuation, stock price, and market status.

Is Telomere Therapeutics a public or private company?

Telomere Therapeutics is a private company.

What is the current stock price of Telomere Therapeutics?

Telomere Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is Telomere Therapeutics worth (valuation)?

Valuation information for Telomere Therapeutics is not publicly available.

Can I buy Telomere Therapeutics stock?

Telomere Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Telomere Therapeutics's last funding round?

Telomere Therapeutics's most recent funding round was Accelerator on December 13, 2023.

Who are the main investors in Telomere Therapeutics?

Key investors in Telomere Therapeutics include Invivo Partners.

Will Telomere Therapeutics IPO soon?

No public IPO plans have been announced for Telomere Therapeutics.

How can I track Telomere Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Telomere Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBarcelona
Employee Range4
Year Founded2020
Last FundingDec 13, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?